The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects.
about
Economics of Team-based Care in Controlling Blood Pressure: A Community Guide Systematic ReviewCost-Effectiveness of Saxagliptin versus Acarbose as Second-Line Therapy in Type 2 Diabetes in ChinaRefitting of the UKPDS 68 risk equations to contemporary routine clinical practice data in the UK.Biologic rheumatoid arthritis therapies: do we need more comparative effectiveness data?Cost-effectiveness of dapagliflozin versus DPP-4 inhibitors as an add-on to Metformin in the Treatment of Type 2 Diabetes Mellitus from a UK Healthcare System PerspectiveCost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China.Predicting Productivity Losses from Health-Related Quality of Life Using Patient Data.Improving valuation sampling of EQ-5D health states.Treatment of type 2 diabetes with saxagliptin: a pharmacoeconomic evaluation in ArgentinaEvaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United KingdomMapping SF-36 onto the EQ-5D index: how reliable is the relationship?The use of the EQ-5D preference-based health status measure in adults with Type 2 diabetes mellitus.Economic evaluations of adult weight management interventions: a systematic literature review focusing on methods used for determining health impacts.A systematic review and critical assessment of health state utilities: weight change and type 2 diabetes mellitus.Cost-effectiveness of exenatide twice daily vs insulin glargine as add-on therapy to oral antidiabetic agents in patients with type 2 diabetes in China.A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK.Biological therapies for the treatment of severe psoriasis in patients with previous exposure to biological therapy: a cost-effectiveness analysis.Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.COST-EFFECTIVENESS OF TREATMENTS FOR MILD-TO-MODERATE OBSTRUCTIVE SLEEP APNEA IN FRANCE.The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus.Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration.Estimating informal care inputs associated with EQ-5D for use in economic evaluation.An economic analysis of continuous positive airway pressure for the treatment of obstructive sleep apnea-hypopnea syndrome.Health economic evaluation of controlled and maintained physical exercise in the prevention of cardiovascular and other prosperity diseases.Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.The impact of the overactive bladder on health-related utility and quality of life.Impact of Behçet's syndrome on health-related quality of life: influence of the type and number of symptoms.Importance of health system context for evaluating utilization patterns across systems
P2860
Q28083249-89BDF1E2-B638-4BB8-B7D6-030EA01B634FQ28553675-37F75307-19D2-46FA-8794-017A508A8F50Q30863970-E46BF9F5-33D4-4287-AEC9-984C131CFD82Q34183220-51CAB895-6520-40E2-B939-0EDB1D6841C4Q35833876-3740EC2F-2237-494A-8643-8180A9F778DDQ36180337-AE47D370-A919-48CB-96D3-7F6F3EFC767EQ36330713-06F4F95B-51AF-4950-8115-2C18231F828AQ36650886-FB942D84-0D76-4F22-AA21-B50409AF36F4Q36835225-8C098606-98C5-4417-A3B8-E1246F45B947Q36897192-9DC9193B-86F5-4292-A35D-991FD56E855BQ37194965-B29874AD-51D4-43D6-A16A-C69532F47F14Q37851559-2C3436A9-F04B-4523-87D9-56E1DF70130CQ37996073-F574A4D2-8BD6-405E-8EBA-F0A5BA299853Q38052636-81B08E22-0A4E-4631-8AF4-F2EB0BFEDCDCQ38815279-5D47F956-4E39-4A22-8E5F-8B0AAF7F917DQ39069412-F41FABF6-CC2D-4B91-ACB6-EE935969B9FCQ39070719-CAFA978E-9B77-4909-9A5D-04BD68F8A4D0Q39451601-D3353299-26CE-4E46-AE88-D080F5BF275DQ40865077-C6F9FA1A-BDDD-4810-8593-942ED8F9F9B8Q41148389-DA6A32DB-AE88-4791-97EB-3F8904DA14E4Q41570665-5114A806-E012-4FB0-98E8-36CA1EF24FF6Q44889025-3FDC1DB9-E885-4D54-B1F9-B5B4546DFE17Q48413504-9CBEBF65-D5AF-442E-9E5F-12EDA6060D86Q49037111-37451BB7-CF67-4465-A3DF-AD581CE8AE10Q51699823-656A17C2-9477-4212-8777-B06A27786047Q51917722-94B208A3-F3B0-4B3E-A48E-E4DF86375459Q53067069-38A25E5C-8799-4DB4-8F4F-3F7124E05419Q57153094-0E428CC9-8F6E-4634-8147-94D03ADC40B5
P2860
The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
The routine collation of healt ...... rom the first 20,000 subjects.
@ast
The routine collation of healt ...... rom the first 20,000 subjects.
@en
type
label
The routine collation of healt ...... rom the first 20,000 subjects.
@ast
The routine collation of healt ...... rom the first 20,000 subjects.
@en
prefLabel
The routine collation of healt ...... rom the first 20,000 subjects.
@ast
The routine collation of healt ...... rom the first 20,000 subjects.
@en
P2093
P1433
P1476
The routine collation of healt ...... rom the first 20,000 subjects.
@en
P2093
Craig J Currie
John R Peters
Phil McEwan
Tunia C Patel
P304
P356
10.1111/J.1524-4733.2005.00046.X
P50
P577
2005-09-01T00:00:00Z